Sitaxsentan STRIDEs ahead in pulmonary arterial hypertension

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1494, 2005-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

By Horn Evelyn M Widlitz Allison C Barst Robyn J

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1483-1492

Informa Healthcare

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Tadalafil: In Pulmonary Arterial Hypertension

By Croxtall Jamie D. Lyseng-Williamson Katherine A.

Drugs, Vol. 70, Iss. 4, 2010-03 ,pp. : 479-488

Adis International

Access to resources Recommend Favorite

Terguride for pulmonary arterial hypertension

By Antoniu Sabina A

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 11, 2011-11 ,pp. : 1333-1335

Informa Healthcare

Access to resources Recommend Favorite

Sitaxentan: In Pulmonary Arterial Hypertension

By Scott Lesley J.

Drugs, Vol. 67, Iss. 5, 2007-01 ,pp. : 761-770

Adis International

Access to resources Recommend Favorite